Bruker Corporation (NASDAQ:BRKR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Bruker Corporation (NASDAQ:BRKR) have received an average rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $53.7143.

Several analysts have commented on BRKR shares. Wells Fargo & Company increased their target price on Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a report on Monday, December 29th. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Rothschild & Co Redburn initiated coverage on Bruker in a research report on Thursday, November 20th. They issued a “buy” rating and a $60.00 target price for the company. Finally, Guggenheim raised their price target on shares of Bruker from $53.00 to $58.00 and gave the company a “buy” rating in a report on Monday, January 26th.

Bruker Trading Up 0.1%

Bruker stock opened at $44.29 on Friday. Bruker has a 12 month low of $28.53 and a 12 month high of $59.40. The company has a market capitalization of $6.73 billion, a price-to-earnings ratio of -276.81, a price-to-earnings-growth ratio of 5.81 and a beta of 1.17. The business’s fifty day simple moving average is $48.32 and its two-hundred day simple moving average is $40.45. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. The business had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. Bruker’s revenue was down .5% compared to the same quarter last year. During the same period last year, the business earned $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, equities analysts predict that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were issued a $0.05 dividend. The ex-dividend date was Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is currently -125.00%.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $49.20, for a total value of $98,400.00. Following the completion of the sale, the vice president owned 128,443 shares of the company’s stock, valued at $6,319,395.60. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the sale, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 15,233 shares of company stock valued at $726,487. 27.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bruker

Large investors have recently made changes to their positions in the company. Orbis Allan Gray Ltd purchased a new stake in shares of Bruker during the 2nd quarter valued at about $192,735,000. AQR Capital Management LLC grew its position in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares during the period. Sculptor Capital LP increased its holdings in Bruker by 18.3% during the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after buying an additional 476,363 shares during the last quarter. Brown Advisory Inc. raised its position in Bruker by 13.9% in the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after acquiring an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. boosted its stake in shares of Bruker by 61.6% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after acquiring an additional 796,510 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.